| Non-antiviral group, n = 139 | Antival group, n = 157 | p value |
---|---|---|---|
Age, years | 56 (49–65) | 57 (49–65) | 0.722 |
Male sex, n (%) | 115 (82.7) | 127 (80.9) | 0.682 |
ALT, IU/m | 35 (25–54) | 35 (26–51) | 0.760 |
AST, IU/ml | 37 (28–56) | 40 (30–61.5) | 0.494 |
ALP, IU/L | 93 (75-140.5) | 96 (73.5–119) | 0.462 |
ALB, g/L | 40.5 (36.9–43.2) | 39.5 (36.0–42.6) | 0.159 |
Total bilirubin, µmol/L | 17.2 (14.1–25.0) | 17.9 (13.6–23.5) | 0.544 |
PT, s | 11.4 (10.8–12.2) | 11.5 (11.0–12.35) | 0.236 |
AFP, ng/ml | 8.1 (2.8-310.1) | 156.3 (16.5–1038.8) | < 0.001 |
PLT, 109/L | 95 (88–183) | 97 (92.5–207) | 0.026 |
Satellite nodules, n (%) | 17 (12.2) | 29 (18.5) | 0.139 |
Capsular, n (%) | 107 (77.0) | 126 (80.2) | 0.492 |
Moderate/poor tumor differentiation, n (%) | 54 (38.8) | 57 (36.3) | 0.652 |
Vascular invasion, n (%) | 42 (30.2) | 23 (14.6) | 0.001 |
Tumor size, cm | 6 (3.5–7.0) | 5 (3–8) | 0.199 |
Multiple tumor, n (%) | 22 (15.8) | 22 (14.0) | 0.363 |
Cirrhosis, n (%) | 95 (68.3) | 101 (64.3) | 0.466 |
Hypertension, n (%) | 40 (28.8) | 39 (24.8) | 0.445 |
Diabetes mellitus, n (%) | 26 (18.7) | 26 (16.6) | 0.628 |
History of smoking, n (%) | 55 (39.6) | 62 (39.5) | 0.989 |
Alcohol abuse, n (%) | 54 (38.8) | 52 (33.1) | 0.305 |
HBeAg positive, n (%) | 27 (19.4) | 24 (15.2) | 0.347 |
Child–Pugh score |  |  | 0.135 |
 A | 135 | 156 |  |
 B | 4 | 1 |  |
BCLC stage | Â | Â | 0.005 |
 Very early (0) | 10 | 17 |  |
 Early (A) | 38 | 61 |  |
 Intermediate (B) | 48 | 56 |  |
 Advanced (C) | 43 | 23 |  |